Dr. William H. Rastetter has been the Chairman of the company since November 2011.Prior to that, he served as interim Chief Executive Officer from February 2012 to October 2012. Dr. Rastetter is a Co-Founder of Receptos Inc where he served as a Director and Chairman of the Board from 2009 to 2015. Previously, he served as an acting Chief Executive Officer and Chairman of Illumina Inc., and as Director of Illumina Inc. He also worked as a Partner at the venture capital firm of Venrock from 2006 to February 2013. Prior to that, Dr. Rastetter served as the Executive Chairman of Biogen Idec from 2003 to 2005. He currently serves as the Chairman of Neurocrine Biosciences Inc, Cerulean Pharma Inc, Grail Inc, and as a Director of Regulus Therapeutics Inc. Dr. Rastetter also serves as a strategic advisor to Leerink Partners, Advisor to Illumina Ventures and on the Board of Trustees of the California Institute of Technology.

J. Scott Wolchko has been the President, Chief Executive Officer and a Director of the company since December 2015. Previously, he served as the company's Chief Operating Officer and prior to that, as the Chief Financial Officer of the company. Before joining Fate Therapeutics, he was the Chief Financial Officer of Bocada Inc and started his career at Morgan Stanley & Co. as an Investment Banker.

Mr. Edward Dulac has been the Chief Financial Officer of the company since August 2020. Prior to this role, he served as Vice President, Business Development and Strategy at Celgene Corp. Previously, he held various roles at Celgene Corp. Prior to Celgene, Mr. Dulac worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers and in corporate finance at Pfizer.

Mr. Mark Plavsic has been the Chief Technology Officer of the company since 2021. Prior to this, he served as the Chief Technical Officer at Lysogene. Previously he served as the Senior Vice President Technology Development & Manufacturing at Torque Therapeutics and also held various roles at Sanofi Genzyme, AstraZeneca, Q-One Biotech, and Life Technologies.

Dr. Yu-Waye (Wayne) Chu has been the Chief Medical Officer of the company since February 2022. Prior to this, he served as the Senior Vice President of Clinical Development since February 2020 and also as the Vice President of Clinical Development since April 2019. Dr. Chu has served in various leadership roles in Genentech Inc from January 2009 to April 2019.